Xencor, Inc. - Common Stock (NQ:XNCR)

25.63 +0.79 (+3.18%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xencor, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference

September 20, 2021

From Xencor, Inc.

Via Business Wire

The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration ↗

August 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

Topics Intellectual Property

Return on Capital Employed Insights for Xencor ↗

August 20, 2021

After pulling data from Benzinga Pro it seems like during Q2, Xencor (NASDAQ:XNCR) earned $9.09 million, a 157.98% increase from the preceding quarter. Xencor also posted a total...

Via Benzinga

Xencor's Earnings: A Preview ↗

May 04, 2021

On Wednesday, May 05, Xencor (NASDAQ:XNCR) will release its latest earnings report. Check out Benzinga's preview to understand the implications. What Are Earnings, Net Income,...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

August 20, 2021

On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) was the largest firm on a market cap basis to set a new 52-...

Via Benzinga

Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China ↗

August 17, 2021

Incyte Corporation (NASDAQ: INCY) and InnoCare have entered into a collaboration and license agreement to develop and commercial tafasitamab in Greater...

Via Benzinga

Xencor, inc (XNCR) Q2 2021 Earnings Call Transcript ↗

August 04, 2021

XNCR earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Xencor Reports Second Quarter 2021 Financial Results

August 04, 2021

From Xencor, Inc.

Via Business Wire

Xencor to Present at Upcoming Investor Conferences

August 02, 2021

From Xencor, Inc.

Via Business Wire

Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021

July 28, 2021

From Xencor, Inc.

Via Business Wire

Xencor to Present at the Jefferies Virtual Healthcare Conference

May 27, 2021

From Xencor, Inc.

Via Business Wire

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings ↗

August 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Earnings Scheduled For August 4, 2021 ↗

August 04, 2021

Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to...

Via Benzinga

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19

May 26, 2021

From Xencor, Inc.

Via Business Wire

Bristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 Antibodies ↗

May 25, 2021

Xencor Inc (NASDAQ: XNCR has entered into a technology license agreement with Bristol-Myers Squibb Co (NYSE: BMY), under which BMY will have non-exclusive access...

Via Benzinga

Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19

May 25, 2021

From Xencor, Inc.

Via Business Wire

Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference

May 12, 2021

From Xencor, Inc.

Via Business Wire

Xencor Inc (XNCR) Q1 2021 Earnings Call Transcript ↗

May 06, 2021

XNCR earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Xencor Reports First Quarter 2021 Financial Results

May 05, 2021

From Xencor, Inc.

Via Business Wire

Xencor Doses First Subject in Phase 1 Study of XmAb®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases

April 28, 2021

From Xencor, Inc.

Via Business Wire

Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021

April 28, 2021

From Xencor, Inc.

Via Business Wire

The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex ↗

April 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,...

Via Benzinga

The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split ↗

April 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ...

Via Benzinga

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021

April 10, 2021

From Xencor, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.